<DOC>
	<DOCNO>NCT00905515</DOCNO>
	<brief_summary>This study design optimize calcineurin immunosuppressive regimen evaluate immunological non-immunological marker may explain mechanistic difference agent effect .</brief_summary>
	<brief_title>Optima : Optimizing Prograf Therapy Maintenance Allografts II</brief_title>
	<detailed_description>One major challenge transplantation past two decade manage long-term renal function . Serum creatinine commonly use serum marker renal function . However serum creatinine insensitive detect small decrease glomerular filtration rate ( GFR ) . Another marker renal function cystatin C. Dharnidharka et al conclude cystatin C superior serum creatinine marker kidney function since cystatin C sensitive marker serum creatinine detect decrease GFR . Pirsch et al report tacrolimus-treated patient low incidence severe acute rejection well lipid profile cyclosporine-treated patient . Cardiovascular disease primary cause premature death renal transplant recipient . Current immunosuppressive protocol often elevate cardiovascular disease risk factor hypertension , hyperlipidemia , obesity diabetes . This study design optimize calcineurin immunosuppressive regimen ensure best possible long-term outcome renal transplantation .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patient recipient cadervic live donor renal transplant . Patient 18 year age time transplant . Patient least 6 month posttransplant . Patient cyclosporinebased immunosuppressive regimen since transplant . Patient function allograft Cockcroft/Gault estimate creatinine clearance &gt; or= 35 mL/min within four week prior randomization . Patient legal guardian sign dated Institutional Review Board ( IRB ) approve informed consent document willing able follow study procedure . Females pregnant agree practice effective birth control receive immunosuppressant medication . Patient recipient solid organ transplant kidney . Patient experience biopsyconfirmed , acute rejection , ( Banff 97 criterion ) within 3 month randomization require treatment , define antilymphocyte therapy , corticosteroid , increase number dose immunosuppressant medication . Patient recurrence primary renal disease , de novo renal disease . Patient urine protein &gt; 1.5g/24 hour two successive urinalysis send report laboratory indicate albuminuria great 2+ within 6 month prior enrollment . Patient estimate creatinine clearance &lt; 35 mL/min calculate use Cockcroft/Gault formula within four week prior randomization . Patient change adjunctive immunosuppressant therapy within one month randomization . Patient pregnant lactating . Patient know carrier HIV virus . Patient know suspected malignancy ( except treat squamous basal cell skin cancer ) &lt; 5 year randomization history posttransplant lymphoproliferative disease ( PTLD ) . Patient known hypersensitivity tacrolimus , excipients drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Immunosuppressive Agents</keyword>
</DOC>